Naltrexone Alone and With Sertraline for the Treatment of Alcohol Dependence in Alaska Natives and Non‐Natives Residing in Rural Settings: A Randomized Controlled Trial
- 28 June 2008
- journal article
- research article
- Published by Wiley in Alcohol: Clinical and Experimental Research
- Vol. 32 (7), 1271-1283
- https://doi.org/10.1111/j.1530-0277.2008.00682.x
Abstract
Background: Access to specialty alcoholism treatment in rural environments is limited and new treatment approaches are needed. The objective was to evaluate the efficacy of naltrexone alone and in combination with sertraline among Alaska Natives and other Alaskans living in rural settings. An exploratory aim examined whether the Asn40Asp polymorphism of the μ‐opioid receptor gene (OPRM1) predicted response to naltrexone, as had been reported in Caucasians. Methods: Randomized, controlled trial enrolling 101 Alaskans with alcohol dependence, including 68 American Indians/Alaska Natives. Participants received 16 weeks of either (1) placebo (placebo naltrexone + placebo sertraline), (2) naltrexone monotherapy (50 mg naltrexone + sertraline placebo) and (3) naltrexone + sertraline (100 mg) plus nine sessions of medical management and supportive advice. Primary outcomes included Time to First Heavy Drinking Day and Total Abstinence. Results: Naltrexone monotherapy demonstrated significantly higher total abstinence (35%) compared with placebo (12%, p = 0027) and longer, but not statistically different, Time to First Heavy Drinking Day (p = 0.093). On secondary measures, naltrexone compared with placebo demonstrated significant improvements in percent days abstinent (p = 0.024) and drinking‐related consequences (p = 0.02). Combined sertraline and naltrexone did not differ from naltrexone alone. The pattern of findings was generally similar for the American Indian/Alaska Native subsample. Naltrexone treatment response was significant within the group of 75 individuals who were homozygous for OPRM1 Asn40 allele. There was a small number of Asp40 carriers, precluding statistical testing of the effect of this allele on response. Conclusions: Naltrexone can be used effectively to treat alcoholism in remote and rural communities, with evidence of benefit for American Indians and Alaska Natives. New models of care incorporating pharmacotherapy could reduce important health disparities related to alcoholism.Keywords
This publication has 79 references indexed in Scilit:
- An Evaluation of μ-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol DependenceArchives of General Psychiatry, 2008
- Opioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative StudyAlcohol: Clinical and Experimental Research, 2007
- Naltrexone Depot for Treatment of Alcohol Dependence: A Multicenter, Randomized, Placebo‐Controlled Clinical TrialAlcohol: Clinical and Experimental Research, 2004
- Effect of the A118G polymorphism on binding affinity, potency and agonist‐mediated endocytosis, desensitization, and resensitization of the human mu‐opioid receptorJournal of Neurochemistry, 2004
- Alaska Native Mortality, 1979–1998Public Health Reports®, 2003
- The prevalence of posttraumatic stress disorder among American Indian Vietnam veterans: Disparities and contextJournal of Traumatic Stress, 2002
- μ opioid receptor gene variants: lack of association with alcohol dependenceMolecular Psychiatry, 1997
- Controlled drinking after 25 years: how important was the great debate?Addiction, 1995
- A Pilot Study of Depression Among American Indian Patients with Research Diagnostic CriteriaAmerican Indian and Alaska Native Mental Health Research, 1987
- Alcohol dependence syndrome: Measurement and validation.Journal of Abnormal Psychology, 1982